


RESEARCH ARTICLE

Impact of iron fortification on anaemia and iron deficiency among pre-school children living in Rural Ghana

Samuel Kofi Tchum^{1,2*}, Fared Kow Arthur¹, Bright Adu³, Samuel Asamoah Sakyi⁴, Latifatu Alhassan Abubakar², Dorcas Atibilla², Seeba Amenga-Etego², Felix Boakyee Oppong², Francis Dzabeng², Benjamin Amoani⁵, Thomas Gyan², Emmanuel Arhin⁶, Kwaku Poku-Asante²

1 Department of Biochemistry and Biotechnology, College of Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, **2** Kintampo Health Research Centre, Ghana Health Service, Kintampo-North, Ghana, **3** Department of Immunology, College of Health Sciences, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana, **4** Department of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, **5** Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana, **6** Faculty of Earth and Environmental Sciences, Department of Earth Science, C K. Tedam University of Technology and Applied Sciences, Navrongo, Ghana

* kofi.tchum@kintampo-hrc.org



OPEN ACCESS

Citation: Tchum SK, Arthur FK, Adu B, Sakyi SA, Abubakar LA, Atibilla D, et al. (2021) Impact of iron fortification on anaemia and iron deficiency among pre-school children living in Rural Ghana. *PLoS ONE* 16(2): e0246362. <https://doi.org/10.1371/journal.pone.0246362>

Editor: Francois Blachier, INRAE, FRANCE

Received: November 14, 2020

Accepted: January 18, 2021

Published: February 11, 2021

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0246362>

Copyright: © 2021 Tchum et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are available from figshare: <https://figshare.com/s/48673d5ea8e5bb2d7c83>

Funding: The author(s) received no specific funding for this work.

Abstract

Anaemia in young sub-Saharan African children may be due to the double burden of malaria and iron deficiency. Primary analysis of a double-blind, cluster randomized trial of iron containing micronutrient powder supplementation in Ghanaian children aged 6 to 35 months found no difference in malaria risk between intervention and placebo groups. Here, we performed a secondary analysis of the trial data to assess the impact of long-term prophylactic iron fortificant on the risk of iron deficiency and anaemia in trial subjects. This population-based randomized-cluster trial involved 1958 children aged between 6 to 35 months, identified at home and able to eat semi-solid foods. The intervention group (n = 967) received a daily dose containing 12.5 mg elemental iron (as ferrous fumarate), vitamin A (400 µg), ascorbic acid (30 mg) and zinc (5 mg). The placebo group (n = 991) received a similar micronutrient powder but without iron. Micronutrient powder was provided daily to both groups for 5 months. At baseline and endline, health assessment questionnaires were administered and blood samples collected for analysis. The two groups had similar baseline anthropometry, anaemia, iron status, demographic characteristics, and dietary intakes (p > 0.05). Of the 1904 (97.2%) children who remained at the end of the intervention, the intervention group had significantly higher haemoglobin (p = 0.0001) and serum ferritin (p = 0.0002) levels than the placebo group. Soluble transferrin receptor levels were more saturated among children from the iron group compared to non-iron group (p = 0.012). Anaemia status in the iron group improved compared to the placebo group (p = 0.03). Continued long-term routine use of micronutrient powder containing prophylactic iron reduced anaemia, iron deficiency and iron deficiency anaemia among pre-school children living in rural Ghana's malaria endemic area.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Anaemia prevalence in children under 5 years old was estimated to be 43% globally in 2011 and was higher (71%) in central and western Africa [1]. In Ghana, the prevalence of anaemia, iron deficiency and iron deficiency anaemia among pre-school children in 2017 were 35.6%, 21.5% and 12.2% respectively [2]. Early childhood anaemia has been associated with reduced cognitive ability, developmental delays and disability [3,4]. Similarly, zinc deficiency is thought to be as prevalent as iron deficiency affecting about 293 million children below the age of five years [5]. Despite the significant physiological roles of micronutrient in human health, their deficiencies are a universal health burden, particularly among young children in developing countries [6]. The multiple micronutrient powder (MNP) contains a mixture of at least iron, zinc, and vitamin A and is recommended by the World Health Organization (WHO) as a treatment therapy to prevent malnutrition in children and during health emergencies [7]. As an intervention to curb the universal health burden of micronutrient deficiencies, vitamin A and zinc supplementation for children, and fortification of foods with iron and iodine, have been considered the most cost-effective approach [8]. MNP with iron (iron-MNP) given to pre-school children improved their motor and cognitive performance and mitigated severe anaemia [9,10].

In malaria endemic regions, morbidity due to iron deficiency anaemia may be further worsened by *Plasmodium falciparum* infections characterized by excessive breakdown of both infected and uninfected erythrocytes thus contributing to lower blood haemoglobin levels [11–15]. More data is needed to ascertain whether provision of long-term continued prophylactic iron-MNP to children aged 6 to 35 months living in malaria endemic areas will reduce iron deficiency anaemia (IDA) [16–18]. In 2003, a randomized placebo-controlled trial conducted in Pemba, Zanzibar involving 32,000 pre-school Tanzanian children was stopped promptly on the advice from the trial's Data Safety Monitoring Board (DSMD) due to higher hospitalizations or mortality rate in the iron group [19]. However, a further secondary subgroup analysis involving recruited iron-replete children at baseline studies discovered a limitation on the risk of adverse events resulting in ethical difficulties and complicated study designs in malaria endemic areas [19]. The UNICEF and WHO joint statement was uncertain about MNP use, since the absorption characteristics differ considerably from iron syrups or tablets if given to children aged between 6 and 36 months [20]. In 2006, the joint statement was amended to specifically recommend home fortification of foods plus iron-MNP to children at risk of iron deficiency and anaemia [21]. Indeed, primary analysis of the current trial data showed no difference in malaria risk between the iron-MNP and placebo groups [22,23]. The WHO thus recommended in 2016 that in heavily malaria transmission areas, pre-school children at risk of iron deficiency and anaemia should be provided with oral iron intervention if they have access to anti-malaria intervention strategies (insecticide-treated bed-nets, anti-malarial drug therapy and vector-control programmes) [24]. Here, we present a secondary analysis of the double-blind, cluster randomized trial data [25], and successfully show the impact of long-term prophylactic iron-MNP on the risk of iron deficiency and anaemia among pre-school children living in malaria endemic areas in Ghana.

Materials and methods

Ethical considerations

The study protocol was reviewed and approved by the ethics committees of the Ghana Health Service, Food and Drugs Authority of Ghana, Kintampo Health Research Centre and Hospital for Sick Children (SickKids), Canada. This current study is a secondary analysis of data from the trial registered at ClinicalTrials.gov (Identifier: NCT01001871) [25]. The trial was overseen

by an independent Data and Safety Monitoring Board (DSMB), which was constituted in October 2009 and held three meetings during the trial. Members of the DSMB included international and local health policy makers with expertise in randomized controlled trials, nutrition, paediatrics, statistics and social sciences. The DSMB's statistician summarized the compiled outcome data at the end of the recruitment phase and half-way via the intervention stage for any serious adverse effects. The children's primary caregivers consented to participate in the study. For the interim analysis, if there were any serious adverse events (i.e. hospital admissions or deaths) in the iron group than the non-iron group, the agreement *a priori* was that the study would be terminated.

Study area and design

This study was a population-based randomized-cluster trial conducted in the Bono (formerly Brong-Ahafo) Region of Ghana. Details of the study area and design have been previously reported. In brief, the study was conducted in Wenchi and Tain, which are two contiguous districts with high malaria transmission in the Region [26]. In 2014, severe-moderate anaemia prevalence among children aged 6–59 months in Bono was 34% according to the Ghana Demographic and Health Survey [1,27]. The trial participants were infants and young children, identified at home and able to eat semi-solid foods (with or without breast milk). For five months, all participants received daily MNP without or with iron (12.5 mg) added to complementary meals. Children who had severe anaemia (haemoglobin < 70.0 g / L), severe malnutrition (weight-for-length z-score < -3.0), or who received iron in supplements within the past 6 months or chronic disease were excluded from the study. The study was conducted in the rainy season during high malaria transmission which allowed for optimum anaemia and iron status assessment.

Recruitment of subjects

A detailed description of subject recruitment and randomization procedures for the trial has been previously reported elsewhere [25]. Briefly, between March and April 2010, eligible children (6 to 35 months old) were enrolled and randomized (ratio 1:1) to receive either iron-MNP group or MNP with no iron group (MNP-Sprinkles[®] Mumbai, India). A cluster comprised one or more households in the same compound with at least one child enrolled and to prevent cross contamination between the groups via food sharing, a cluster randomization design was employed using (in house written program) a computer-generated model [25]. This simple random allocation was carried out at the cluster level because the participants lived in same compound with different or extended families in the rural communities. Therefore, this randomization scheme also facilitated the monitoring of participants, particularly those who moved within or outside the study area. All enrolled children received insecticide treated net (ITN). Sachets without or with iron were similar except a subtle 'A' or 'B' labelled markings and both caregivers and study team were blinded. The iron-MNP dose contained elemental iron (12.5 mg) in microencapsulated ferrous fumarate, vitamin A (400 µg), ascorbic acid (30 mg) and zinc (5 mg) [25,28] The control (non-iron) group received a similar MNP without iron. Each day for a 5-month period, 1 sachet of MNP (equivalent of 12.5 mg iron for the iron group) was mixed with a small quantity of semi-solid meals and given to the children. Once a week, field research assistants visited the home of each child to collect morbidity data (including axillary temperature), assess adherence to ITN use and MNP intervention and to supply replenishment. Caregivers saved empty and any unused packets which were counted during visits. The adherence was determined by multiplying the actual number of packages used by 100, divided by the estimated amount used (given perfect adherence). Children were further monitored an extra month without the MNP at the end of the intervention.

Specimen and data collection

At baseline (BL) and endline (EL) finger or heel prick blood (about 500 μ L) sample was collected for haematological, malaria microscopy, acute phase reactant and iron biomarker analyses. Blood haemoglobin (Hb) level was measured directly using HemoCue Hb 201⁺ analyzer (HemoCue AB, Angelholm, Sweden) and severely anaemic were referred for treatment. At baseline, malaria rapid diagnostic test (RDT) (Paracheck Pf[®] Device, Orchid Biomedical Systems, Verna, Goa, India) was initially performed and children with positive results were treated for malaria as described [25]. After recovery, participants were enrolled if all other inclusion criteria were met. If a child is febrile (i.e. axillary temperature $> 37.5^{\circ}\text{C}$) or febrile 48 hours ago, 100 μ L capillary blood sample was collected into 0.5 mL EDTA tube for full blood count, malaria rapid and blood smear test (for parasitaemia and speciation) during the study as previously described [25].

Specimen processing and analysis

Thin blood films were fixed with methanol and the smears stained with Giemsa for microscopy examination. Each sample slide was read by two independent microscopists and if discrepancy between the two readers was over 50%, a third microscopist was consulted [25]. Full blood count (FBC) was measured by the haematology auto-analyzer (Horiba ABX Micros 60-OT-CT-OS-CS, Montpellier, France) and C-reactive protein (CRP) by immune-turbidimetrically using the QuikRead 101 analyzer (Orion Diagnostica, Espoo, Finland). Red blood cell zinc protoporphyrin (ZPP) was measured using a haematofluorometer (Model 206D, Aviv Biomedical Inc. Lakewood, NJ, USA). Indirect enzyme-linked immunosorbent assay (ELISA) was used to measure ferritin (Fn) (Spectro Ferritin S-22, Ramco Laboratories Inc. USA) and transferrin receptor (TfR) (TFC-94, Ramco Laboratories Inc. USA) levels as described in the following procedures [25].

Statistical analysis

We tested the hypothesis that anaemia and iron status would be significantly improved among the children in the iron group than those in the non-iron. Descriptive statistics were used to summarize the study variables. Difference in baseline characteristics between the children in the iron and non-iron group was studied using two-sample Wilcoxon rank-sum (continuous variables) and Chi-squared test for categorical variables.

In studying the effect of the iron intervention on various indicators (anaemia (Hb < 100 g / L), iron deficiency (Ferritin < 30 μ g / L, ZPP > 52 μ mol / mol haeme), iron deficiency anaemia (IDA), (Hb < 100 g / L, Ferritin < 30 μ g / L) status, mixed effect models were used to perform a difference-in-difference analysis while controlling for the compound and individual level correlation [29–31].


Using logistic regression, the risk of anaemia, iron deficiency and iron deficient anaemia were compared between the iron and non-iron group. Generalized estimating equation with robust standard errors was used to obtain population-averaged estimates and to account for the household level clustering. Parameter estimates were reported as odds ratio with 95% confidence intervals. Separate models were considered for anaemia, iron deficiency and iron deficient anaemia. In all the models, we adjusted for child's age (≤ 12 months, 13–24 months and > 24 months) and sex. Acknowledging that ferritin and ZPP interpretation will be confounded by acute phase response, we excluded these indicators for those children who had an elevated CRP (> 8 mg / L) [32,33]. Also, we adjusted for baseline anaemia, baseline iron deficiency and baseline iron deficient anaemia in the model for anaemia, iron deficiency and iron deficient anaemia respectively. All analyses were carried out on an intention-to-treat (ITT)

basis. Data was analysed using STATA (Stata Statistical Software: Release 11. College Station, TX: StataCorp LP, 2015). $P < 0.05$ was considered statistically significant.

Results

Study participant characteristics

The characteristics of the study population have previously been described elsewhere [25]. In summary, a total of 2220 children aged 6–35 months from 22 communities were screened for eligibility and 262 (11.8%) were excluded according to pre-specified criteria. The remaining 1958 children were randomized to receive either prophylactic micronutrient powder with iron ($n = 967$) or placebo ($n = 991$). Out of the 1958 children enrolled, blood sample was obtained from 1806 (92.2%) after the MNP intervention (Fig 1). By the end of the study (24 weeks), about 3.0% of the participants were lost to follow-up (iron = 67 versus non-iron = 76) for



§: A cluster is a compound representing 1 or more households (or family units) living in the same residence with at least 1 eligible child enrolled in the study, MNP: Micronutrient powder, Fe: iron.

Fig 1. Study profile. Micronutrient powder (MNP), Fe (iron), Children (CHN), Month (mo), Number (n). §: A cluster is a compound representing 1 or more households (or family units) living in the same residence with at least 1 eligible child enrolled in the study.

<https://doi.org/10.1371/journal.pone.0246362.g001>

863.8 child years of total observation time. The lost to follow-up in both groups was due to families moving from the trial area. Adherence to MNP intervention was similar between the groups and ITN use also did not differ [25]. Baseline characteristics of the children were similar between the groups (Table 1).

Association of Hb levels between iron and non-iron MNP participants

A mean Hb levels at baseline were comparable between the non-iron and iron groups (10.29 g / dL versus 10.29 g / dL, $p = 0.904$) (Table 4). However, the overall Hb level in both groups was significantly lower at endline compared to the baseline ($p < 0.001$). The mean Hb level after the intervention was significantly lower in the non-iron group compared to the iron group (9.31 ± 1.5 g / L versus 9.65 ± 1.7 g / L respectively, $p < 0.001$). With a difference in difference estimate of 0.35 g / dL (95% CI: 0.19 g / dL–0.51 g / dL, $p < 0.001$), children in the non-iron group had a mean Hb reduction of 0.35 g / dL compared to those in the iron group (Table 4).

Table 1. Baseline characteristics amongst the children.

Characteristics	Iron Group (n = 894) ^a	Non-iron Group (n = 912) ^a
Number of clusters	736	721
Cluster size, mean (range)	1.6 (1–4)	1.5 (1–5)
Age, mean (SD), mo	19.3 (8.7)	19.1 (8.6)
Gender, n (%)		
Male	458 (51.2)	457 (50.1)
Female	436 (48.8)	455 (49.9)
Anthropometric status		
Wasting, n (%) [95% CI]	83 (9.3) [7.3–11.0]	65 (7.1) [5.7–9.1]
Weight for length Z-score mean (SD) ^b	-0.54 (3.5)	-0.50 (3.4)
Stunted growth, n (%) [95% CI]	64 (14.7) [12.4–17.1]	60 (13.8) [11.5–16.1]
Length for age Z-score, mean (SD) ^b	-0.79 (1.6)	-0.68 (3.6)
Underweight, n (%) [95% CI]	56 (12.9) [10.7–15.4]	46 (10.6) [8.5–12.6]
Weight for age Z-score mean (SD) ^b	-0.87 (1.2)	-0.75 (3.5)
Asymptomatic malaria prevalence, n (%)	216 (24.2%)	224 (24.6%)
Bednet used the previous night, n (%)		
Yes	655 (90.7)	681 (93.0)
No	67 (9.3)	52 (7.0)
Malaria parasitaemia, n, geometric mean, 95% CI count/μL	209, 2713.0 (2197.9–3349.0)	218, 2806.6 (2236.4–3522.3)
Household head education, n (%)		
None	241 (33.3)	228 (31.1)
Basic education	442 (61.1)	439 (59.8)
Secondary education and above	40 (5.6)	67 (9.1)
Moderate anaemia prevalence, n (%)	325 (36.4)	320 (35.1)
Socioeconomic status of household heads, n (%)	855 (100)	890 (100)
High	250 (29.2)	297 (33.4)
Low	605 (70.8)	593 (66.6)

Frequency (n) and percentages (%) of participants, age in months (mo), standard deviation (SD), 95% confidence interval (95% CI).

^a Unit of analysis represents individual participant unless if not stated.

^b Applying approximated WHO growth reference charts (± 2 SD).

<https://doi.org/10.1371/journal.pone.0246362.t001>

Iron-MNP supplementation decreased anaemia in the study children

The prevalence of anaemia was similar between the iron and non-iron group at baseline (36.84% versus 35.66%, $p = 0.618$) (Fig 2). Overall, endline prevalence of anaemia was 58.6% (N = 1059, 95% CI: 56.3% - 60.9%) and was more prevalent in children in the non-iron group than in those who received the iron intervention (62.63% versus 55.52%, $p = 0.003$) (Table 2). Endline prevalence of moderate and severe anaemia were 52.7% (N = 951, 95% CI: 50.3%–55.0%) and 6.0% (N = 108, 95% CI: 5.0% - 7.2%) respectively (Table 2). Additionally, the risk adjusted logistic regression analysis also indicated that the odds of anaemia was significantly higher in the children from the non-iron group compared to those in the iron group (Table 3). In comparing the difference (endline versus baseline) in anaemia prevalence for the iron and non-iron group, anaemia prevalence was 8.29% lower in the children who received the iron supplementation (Fig 2 and Table 4).

Iron-MNP supplementation decreased iron deficiency in the children

Baseline adjusted mean ZPP concentration among children in the non-iron group was similar compared to the iron group (121.8 for non-Fe versus 121.3 $\mu\text{mol} / \text{mol}$ of haeme for iron children) ($p = 0.979$) (Table 2). Similarly, endline adjusted mean ZPP concentration was comparable between the non-iron and the iron group (205.1 for non-iron versus 173.6 $\mu\text{mol} / \text{mol}$ of haeme for iron children) ($p = 0.101$) (Table 2). The prevalence of endline iron deficiency was 24.5% (N = 443, 95% CI: 22.6% - 26.6%) (Table 2). The risk-adjusted logistic regression also




Fig 2. Prevalence of anaemia, iron status between groups at baseline and endline. Plot shows anaemia and iron status prevalence with 95% confidence intervals for each group.

<https://doi.org/10.1371/journal.pone.0246362.g002>

Table 2. Impact of MNP on anaemia and iron status among study participants.

Characteristics	Baseline			Endline		
	Iron Group (n = 894) ^a	Non-iron Group (n = 912) ^a	p-values	Iron Group (n = 894) ^a	Non-iron Group (n = 912) ^a	p-values
Anaemic status	894 (100)	912 (100)		894 (100)	912 (100)	
Non anaemia, n (%)	568 (63.5)	592 (64.9)		401 (44.9)	346 (37.9)	
Moderate anaemia, n (%)	326 (36.5)	321 (35.1)	0.56	455 (50.9)	496 (54.4)	0.03
Severe anaemia, n (%)	-	-		38 (4.2)	70 (7.7)	
Iron status						
Iron deficiency, n (%)	396 (44.3)	422 (46.3)	0.41	178 (19.9)	265 (29.1)	< 0.0001
Iron deficiency anaemia, n (%)	163 (18.2)	163 (17.9)	0.84	85 (9.5)	158 (17.3)	< 0.0001

^a Unit of analysis represents individual participant unless if not stated, standard deviation (SD), number (n), percentage (%), 95% confidence interval (95% CI), Two-sample Wilcoxon rank-sum (Mann-Whitney) for continuous variables and Chi squared/ Fisher's exact tests for categorical variables.

<https://doi.org/10.1371/journal.pone.0246362.t002>

indicated that the chances of iron deficiency in children in the non-iron category were significantly higher than in those in the iron group (Table 3). At baseline, there was no significant difference in the prevalence of iron deficiency between the children in the iron and non-iron arm (44.11% versus. 45.77%) (Table 4). Furthermore, at endline, the prevalence of iron deficiency was significantly lower in children who took the iron supplementation (19.71% versus. 28.56%) (Fig 2 and Table 4).

Iron-MNP supplementation decreased iron deficiency anaemia in the study children

The iron deficiency anaemia endline prevalence was 13.5% (N = 243, 95%: 12.0% - 15.1%) (Table 2). Moreover, the risk-adjusted logistic regression shows that the odds of iron deficiency anaemia was higher in non-iron group compared to the iron group (Table 3). The prevalence of baseline iron deficiency anaemia was comparable between the iron and non-iron participants (Table 4). At endline, the iron group had a substantially lower prevalence of iron deficiency anaemia compared to non-iron group (Table 4).

Discussion

In this study, the use of daily prophylactic micronutrient powder with or without iron as a fortificant in semi-solid meals in children aged 6 to 35 months was assessed for its impact on blood haemoglobin levels, anaemia, iron deficiency (ID) and iron deficiency anaemia (IDA)

Table 3. Effect of MNP on anaemia and iron status among study children.

Outcomes	Study groups	Number (% of children with outcome)	Adjusted odds ratio ^g (95% CI)	p-values
Anaemia	Non-iron	566 (62.1%)	1	0.002
	Iron	493 (55.1%)	0.72 (0.59–0.89)	
Iron deficiency	Non-iron	265 (29.1%)	1	< 0.001
	Iron	178 (19.9%)	0.59 (0.47–0.75)	
Iron deficiency anaemia	Non-iron	158 (17.3%)	1	< 0.001
	Iron	85 (9.5%)	0.47 (0.35–0.64)	

95% confidence interval (95% CI), percentage (%), ^g: Adjusted for child's age and sex. Further adjusted for baseline anaemia, baseline iron deficiency and baseline iron deficiency anaemia in the model for anaemia, iron deficiency and iron deficiency anaemia respectively.

<https://doi.org/10.1371/journal.pone.0246362.t003>

Table 4. Effect of MNP on haemoglobin, anaemia, iron biomarkers and CRP among study participants.

Characteristics	Baseline				Endline				Difference in difference		
	Iron Group	Non-iron Group	Difference	p-values	Iron Group	Non-iron Group	Difference	p-values	Difference	95% CI	p-values
Haemoglobin status											
Haemoglobin mean (SD) (g/dL)	10.29 (± 1.26)	10.29 (± 1.27)	-0.01	0.904	9.65 (± 1.70)	9.31 (± 1.52)	0.34	<0.001	0.35	0.19, 0.51	<0.001
Anaemia status											
Anaemia, (%)	36.84	35.66	1.18	0.618	55.52	62.63	-7.11	0.003	-8.29	-13.96, -2.63	0.004
Iron biomarkers status											
Ferritin (µg/L)	86.99	72.05	14.94	0.263	173.24	147.80	25.44	0.056	10.50	-25.61, 46.61	0.569
Ferritin adjusted (µg/L)	62.00	61.63	0.37	0.975	142.73	115.67	27.06	0.026	26.69	-5.87, 59.24	0.108
Transferrin (ng/m/L)	81.08	86.23	-5.15	0.324	63.16	78.29	-15.13	0.003	-9.97	-23.69, 3.74	0.154
Zinc protoporphyrin (µmol ZPP/mol haeme)	123.91	125.52	-1.61	0.918	179.29	213.85	-34.56	0.027	-32.95	-74.08, 8.18	0.116
Zinc protoporphyrin adjusted (µmol ZPP/mol haeme)	121.30	121.79	-0.49	0.979	173.59	205.13	-31.54	0.101	-31.05	-81.39, 19.28	0.227
Iron deficiency (%)	44.11	45.77	-1.66	0.457	19.71	28.56	-8.85	<0.001	-7.19	-12.90, -1.49	0.013
Iron deficiency anaemia (%)	18.25	17.90	0.35	0.839	9.53	17.35	-7.82	<0.001	-8.18	-12.63, -3.72	<0.001
Inflammation											
C-reactive protein (mg/L)	3.37	3.26	0.11	0.708	4.06	3.97	0.09	0.729	-0.01	-0.72, 0.70	0.983

In the adjusted ZPP, participants with abnormally high CRP levels (due to infection) were excluded. 95% confidence interval (95% CI), percentage (%).

<https://doi.org/10.1371/journal.pone.0246362.t004>

status. This was a secondary analysis of a previous double-blind, cluster randomized trial which assessed the effect of iron supplementation on malaria incidence among pre-school children in rural Ghana [25]. Iron deficiency and iron deficiency anaemia IDA prevalence improved at the end of the intervention among the children in the iron group than those in the non-iron group. These results concord with other iron-MNP studies [34,35]. None the less, other studies have linked ID and IDA prevalence to the impact of MNP intervention equivocally [36–38]. The MNP used in the current study also contained ascorbic acid which is thought to stimulate iron absorption into mucosal cells by preventing the formation of insoluble and unabsorbable iron compounds [39,40]. Of the other components of the MNP, the effect of vitamin A on iron nutrition remains unclear. Some studies found low doses of vitamin A like what was used in the current study to enhance iron absorption [41,42] although high doses (such as 1800 µg) may be detrimental to iron nutrition [43]. In other studies vitamin A did not enhance iron absorption in humans [44]. However, simultaneous use of iron and vitamin A supplements appears to mitigate iron deficiency anaemia [45].

In endemic areas, malaria is a major contributor to anaemia due to haemolysis of both parasitized and unparasitized erythrocytes by the immune system and is characterised by temporary bone marrow dyserythropoiesis [24,46]. In our study, there was no difference in asymptomatic malaria prevalence and parasitaemia between children in the iron-MNP and the non-iron MNP groups at baseline. Indeed, the incidence of malaria was not different between the groups at the end of the study as previously reported [25]. A previous sub-group

analysis of baseline haemoglobin and ZPP concentrations indicated that children from the iron group who were iron replete ($ZPP \leq 52 \mu\text{mol} / \text{mol}$ of haeme) with moderate anaemia had reduced risk of uncomplicated malaria or severe malaria compared to non-iron group children who were iron replete and moderately anaemic at baseline [25]. Paradoxically, whole blood ZPP levels were limited in distinguishing between those with and without an iron deficiency. However, no additional predictive benefit was found even when paired with levels of haemoglobin, but rather overestimated ID prevalence relative to standard cut-off points ($> 52 \mu\text{mol} / \text{mol}$ haeme). These findings from our study is consistent with other MNP studies that used ZPP as additional iron indicator [31,47,48], but contrary to other MNP intervention findings [31,49]. This may be attributed to the differences in ZPP cut-offs used to define iron deficiency, which was lower in our study ($> 52 \mu\text{mol} / \text{mol}$ of haeme) compared to a study in Zanzibar ($> 80 \mu\text{mol} / \text{mol}$ of haeme) [31,49,50]. During intraerythrocytic malaria parasitaemia, most of the host haemoglobin haeme is converted into a nontoxic haeme crystal, haemozoin [51]. Though, erythrocyte zinc protoporphyrin IX is normally present at $0.5 \mu\text{M}$, with a ratio of 1:40000 haemes, it can rise 10-fold in certain anaemias and iron deficient or depletes which is associated with high CRP levels and malaria immunity [52]. Several ZPP cut-offs for defining iron deficiency have been proposed based on the population being studied and the specimen processing method (e.g. washed versus unwashed red blood cells). Blood samples in our study were washed prior to analysis. It appears unwashed red blood cells was used in the Zanzibar trial and this may have led to the higher ZPP cut-off used [19]. The differences in iron status classification between these studies may have affected the comparability of statistical outcomes. One main common finding between our study and that performed in Zanzibar was the significant protective effect of iron to mitigate the risk of iron deficiency and anaemia among young children.

In 2009, a systematic review of 14 studies reported that the provision of iron mitigated the risk of malaria but the effect was reversed when routine malaria management and surveillance were absent [53]. However, none of the studies included iron fortification intervention trials. Our study used powdered iron fortificant (ferrous fumarate) with different absorption characteristics from the iron supplement (provided in the form of iron and folic acid tablets) used in other studies [19]. In addition, iron (ferrous fumarate) microencapsulation may have preserved iron in the food matrix from oxidation and likely delayed peak plasma iron concentrations. [54–56]. This may have reduced the level of freely accessible iron in circulation and mitigated the risk of malaria in the study children [25,57]. In our study, majority of children slept under bed net and at the end of the intervention, there was no increase in malaria incidence in the iron group despite the substantial nutritional benefit observed. Findings from our study support other studies underscoring the importance of iron-MNP as an intervention measure to minimize iron deficiency and associated consequences in malaria endemic areas when adequate malaria infection prevention measures are in place.

Conclusion

Prophylactic iron-MNP continued use decreased anaemia, iron deficiency and iron deficiency anaemia among pre-school children living in rural Ghana's malaria endemic area.

Acknowledgments

We would like to thank the study participants and their caregivers; the KHRC field team and staff; chiefs, opinion leaders and elders of participating communities; participating health facilities; the GHS staff in Wenchi and Tain; the Ethics Boards of KHRC, GHS and SickKids of Canada; the DSMB; and FDA of Ghana.

Author Contributions

Conceptualization: Samuel Kofi Tchum, Fareed Kow Arthur, Bright Adu, Samuel Asamoah Sakyi, Latifatu Alhassan Abubakar, Dorcas Atibilla, Felix Boakye Oppong, Francis Dzabeng, Benjamin Amoani, Thomas Gyan, Emmanuel Arhin, Kwaku Poku-Asante.

Data curation: Samuel Kofi Tchum, Fareed Kow Arthur, Samuel Asamoah Sakyi, Seeba Amenga-Etego, Felix Boakye Oppong, Francis Dzabeng, Benjamin Amoani, Thomas Gyan, Kwaku Poku-Asante.

Formal analysis: Samuel Kofi Tchum, Bright Adu, Samuel Asamoah Sakyi, Dorcas Atibilla, Felix Boakye Oppong, Francis Dzabeng, Benjamin Amoani, Kwaku Poku-Asante.

Funding acquisition: Samuel Kofi Tchum, Kwaku Poku-Asante.

Investigation: Samuel Kofi Tchum, Fareed Kow Arthur, Bright Adu, Samuel Asamoah Sakyi, Latifatu Alhassan Abubakar, Dorcas Atibilla, Kwaku Poku-Asante.

Methodology: Samuel Kofi Tchum, Fareed Kow Arthur, Bright Adu, Samuel Asamoah Sakyi, Latifatu Alhassan Abubakar, Dorcas Atibilla, Felix Boakye Oppong, Francis Dzabeng, Benjamin Amoani, Thomas Gyan, Emmanuel Arhin, Kwaku Poku-Asante.

Project administration: Samuel Kofi Tchum, Latifatu Alhassan Abubakar, Dorcas Atibilla, Kwaku Poku-Asante.

Resources: Samuel Kofi Tchum, Benjamin Amoani, Kwaku Poku-Asante.

Software: Samuel Kofi Tchum, Seeba Amenga-Etego, Felix Boakye Oppong, Francis Dzabeng, Kwaku Poku-Asante.

Supervision: Samuel Kofi Tchum, Fareed Kow Arthur, Bright Adu, Samuel Asamoah Sakyi, Emmanuel Arhin, Kwaku Poku-Asante.

Validation: Samuel Kofi Tchum, Fareed Kow Arthur, Bright Adu, Samuel Asamoah Sakyi, Latifatu Alhassan Abubakar, Dorcas Atibilla, Seeba Amenga-Etego, Felix Boakye Oppong, Francis Dzabeng, Benjamin Amoani, Thomas Gyan, Kwaku Poku-Asante.

Visualization: Fareed Kow Arthur, Seeba Amenga-Etego, Felix Boakye Oppong, Thomas Gyan, Kwaku Poku-Asante.

Writing – original draft: Samuel Kofi Tchum, Fareed Kow Arthur, Bright Adu, Samuel Asamoah Sakyi, Kwaku Poku-Asante.

Writing – review & editing: Samuel Kofi Tchum, Fareed Kow Arthur, Bright Adu, Samuel Asamoah Sakyi, Latifatu Alhassan Abubakar, Dorcas Atibilla, Seeba Amenga-Etego, Felix Boakye Oppong, Francis Dzabeng, Benjamin Amoani, Thomas Gyan, Emmanuel Arhin, Kwaku Poku-Asante.

References

1. Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995–2011: a systematic analysis of population-representative data. *The Lancet Global Health*. 2013; 1(1):e16–e25. [https://doi.org/10.1016/S2214-109X\(13\)70001-9](https://doi.org/10.1016/S2214-109X(13)70001-9) PMID: 25103581
2. Wisconsin-Madison/KEMRI-WellcomeTrust/UNICEF UoGGUo. Ghana Micronutrient Survey 2017. UNICEF-Accra Accra, Ghana; 2017.
3. Black R, Allen L, Bhutta Z, Caulfield L, de Onis M, Ezzati M, et al. Maternal and Child Undernutrition Study Group: Maternal and child undernutrition 1-maternal and child undernutrition: global and regional

- exposures and health consequences. *Lancet*. 2008; 371:243–60. [https://doi.org/10.1016/S0140-6736\(07\)61690-0](https://doi.org/10.1016/S0140-6736(07)61690-0) PMID: 18207566
4. Walter T. Effect of iron-deficiency anemia on cognitive skills and neuromaturation in infancy and childhood. *Food and Nutrition Bulletin*. 2003; 24(4_suppl_1):S104–S10. <https://doi.org/10.1177/15648265030244S207> PMID: 17016952
 5. De-Regil LM, Suchdev PS, Vist GE, Walleser S, Peña-Rosas JP. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. *Evidence-Based Child Health: A Cochrane Review Journal*. 2013; 8(1):112–201.
 6. Horton S, Shekar M, Ajay M. *Scaling up nutrition: What will it cost?: The World Bank*; 2009.
 7. WHO. World Health Organization model list of essential medicines: 21st list 2019. World Health Organization, 2019.
 8. Muthayya S, Rah JH, Sugimoto JD, Roos FF, Kraemer K, Black RE. The global hidden hunger indices and maps: an advocacy tool for action. *PLoS One*. 2013; 8(6).
 9. Zlotkin SH, Christofides AL, Hyder SZ, Schauer CS, Tondeur MC, Sharieff W. Controlling iron deficiency anemia through the use of home-fortified complementary foods. *The Indian Journal of Pediatrics*. 2004; 71(11):1015–9. <https://doi.org/10.1007/BF02828118> PMID: 15572823
 10. Chang S, Zeng L, Brouwer ID, Kok FJ, Yan H. Effect of iron deficiency anemia in pregnancy on child mental development in rural China. *Pediatrics*. 2013; 131(3):e755–e63. <https://doi.org/10.1542/peds.2011-3513> PMID: 23400604
 11. Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. *Am J Trop Med Hyg*. 2001; 64(1–2 Suppl):1–11. <https://doi.org/10.4269/ajtmh.2001.64.1.11425154> PMID: 11425154
 12. Miller JL. Iron deficiency anemia: a common and curable disease. *Cold Spring Harbor perspectives in medicine*. 2013; 3(7):a011866. <https://doi.org/10.1101/cshperspect.a011866> PMID: 23613366
 13. Osman MIH. Renal and Liver Function Tests in Association with Some Haematological Parameters in Malaria Ambulant patients in Shendi locality, River Nile State, SUDAN: 2015. *جامعة شندي*.
 14. Angus BJ. *Pathophysiological aspects of severe Falciparum malaria in Thailand and Ghana: ProQuest Dissertations & Theses*; 2001.
 15. Mak TW, Saunders ME. Immunity to pathogens. *The Immune Response*. 2006:641.
 16. Baldi AJ, Larson LM, Pasricha S-R. Balancing safety and potential for impact in universal iron interventions. *Global Landscape of Nutrition Challenges in Infants and Children*. 93: Karger Publishers; 2020. p. 51–62.
 17. Duke T. *RANDOMISED TRIALS IN CHILD AND ADOLESCENT HEALTH IN DEVELOPING COUNTRIES*. 2017.
 18. Berti C, Faber M, Smuts CM. Prevention and control of micronutrient deficiencies in developing countries: current perspectives. *Nutrition and Dietary Supplements*. 2014; 6:41–57.
 19. Sazawal, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. *Lancet*. 2006; 367(9505):133–43. [https://doi.org/10.1016/S0140-6736\(06\)67962-2](https://doi.org/10.1016/S0140-6736(06)67962-2) PMID: 16413877
 20. WHO/UNICEF. Iron supplementation of young children in regions where malaria transmission is intense and infectious disease highly prevalent: Joint statement. Geneva, Switzerland: World Health Organization and UNICEF. World Health Organization and UNICEF, 2006.
 21. De-Regil LM, Suchdev PS, Vist GE, Walleser S, Pena-Rosas JP. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. *Cochrane database of systematic reviews (Online)*. 2011; 9:CD008959.
 22. Tang M, Frank DN, Hendricks AE, Ir D, Esamai F, Liechty E, et al. Iron in micronutrient powder promotes an unfavorable gut microbiota in Kenyan infants. *Nutrients*. 2017; 9(7):776. <https://doi.org/10.3390/nu9070776> PMID: 28753958
 23. Lemaire M, Islam QS, Shen H, Khan MA, Parveen M, Abedin F, et al. Iron-containing micronutrient powder provided to children with moderate-to-severe malnutrition increases hemoglobin concentrations but not the risk of infectious morbidity: a randomized, double-blind, placebo-controlled, noninferiority safety trial. *The American journal of clinical nutrition*. 2011; 94(2):585–93. <https://doi.org/10.3945/ajcn.110.009316> PMID: 21715512
 24. WHO. *Guidelines: Daily Iron Supplementation in Infants and Children*, WHO Guidelines Approved by the Guidelines Review Committee. World Health Organization, 2016 9241549521.
 25. Zlotkin S, Newton S, Aimone AM, Azindow I, Amenga-Etego S, Tchum K, et al. Effect of iron fortification on malaria incidence in infants and young children in Ghana: a randomized trial. *JAMA*. 2013; 310(9):938–47. <https://doi.org/10.1001/jama.2013.277129> PMID: 24002280

26. Addy-Tayie N. 3D-Printed Microscope Accessory: Affordable Technology for Efficient Diagnostics. 2019.
27. GSS. 2010 Population & Housing Census: Brong-Ahafo Region: Ghana Statistical Service; 2013.
28. IOM. Dietary Reference Intakes Tables and Application: Food and Nutrition Board, Institute of Medicine, National Academies; 1997–2001 [cited 2010]. Available from: <http://www.iom.edu/Activities/Nutrition/SummaryDRIs/DRI-Tables.aspx>.
29. Soldin OP, Miller M, Soldin SJ. Pediatric reference ranges for zinc protoporphyrin. *Clinical biochemistry*. 2003; 36(1):21–5. [https://doi.org/10.1016/s0009-9120\(02\)00405-8](https://doi.org/10.1016/s0009-9120(02)00405-8) PMID: 12554055
30. Lorenz L, Peter A, Poets CF, Franz AR. A review of cord blood concentrations of iron status parameters to define reference ranges for preterm infants. *Neonatology*. 2013; 104(3):194–202. <https://doi.org/10.1159/000353161> PMID: 23989077
31. Teshome EM, Prentice AM, Demir AY, Andang'o PE, Verhoef H. Diagnostic utility of zinc protoporphyrin to detect iron deficiency in Kenyan preschool children: a community-based survey. *BMC hematology*. 2017; 17(1):11. <https://doi.org/10.1186/s12878-017-0082-z> PMID: 28770094
32. Pepys MB. C-reactive protein fifty years on. *Lancet*. 1981; 1(8221):653–7. [https://doi.org/10.1016/s0140-6736\(81\)91565-8](https://doi.org/10.1016/s0140-6736(81)91565-8) PMID: 6110874
33. Verhoef H, West CE, Ndeto P, Burema J, Beguin Y, Kok FJ. Serum transferrin receptor concentration indicates increased erythropoiesis in Kenyan children with asymptomatic malaria. *Am J Clin Nutr*. 2001; 74(6):767–75. <https://doi.org/10.1093/ajcn/74.6.767> PMID: 11722958
34. Thompson J, Biggs B-A, Pasricha S-R. Effects of daily iron supplementation in 2-to 5-year-old children: systematic review and meta-analysis. *Pediatrics*. 2013; 131(4):739–53. <https://doi.org/10.1542/peds.2012-2256> PMID: 23478873
35. Low M, Farrell A, Biggs B-A, Pasricha S-R. Effects of daily iron supplementation in primary-school-aged children: systematic review and meta-analysis of randomized controlled trials. *CMAJ*. 2013; 185(17):E791–E802. <https://doi.org/10.1503/cmaj.130628> PMID: 24130243
36. Bryszewska MA, Laghi L, Zannoni A, Gianotti A, Barone F, Saa T, et al. Bioavailability of microencapsulated iron from fortified bread assessed using piglet model. *Nutrients*. 2017; 9(3):272. <https://doi.org/10.3390/nu9030272> PMID: 28335378
37. Prentice AM, Verhoef H, Cerami C. Iron fortification and malaria risk in children. *JAMA*. 2013; 310(9):914–5. <https://doi.org/10.1001/jama.2013.6771> PMID: 24002276
38. Pasricha S-R, Hayes E, Kalumba K, Biggs B-A. Effect of daily iron supplementation on health in children aged 4–23 months: a systematic review and meta-analysis of randomised controlled trials. *The Lancet Global Health*. 2013; 1(2):e77–e86. [https://doi.org/10.1016/S2214-109X\(13\)70046-9](https://doi.org/10.1016/S2214-109X(13)70046-9) PMID: 25104162
39. Rusu IG, Suharoschi R, Vodnar DC, Pop CR, Socaci SA, Vulturar R, et al. Iron Supplementation Influence on the Gut Microbiota and Probiotic Intake Effect in Iron Deficiency—A Literature-Based Review. *Nutrients*. 2020; 12(7):1993. <https://doi.org/10.3390/nu12071993> PMID: 32635533
40. Blanco-Rojo R, Sandoval-Insausti H, López-García E, Graciani A, Ordovás JM, Banegas JR, et al., editors. Consumption of ultra-processed foods and mortality: a national prospective cohort in Spain. *Mayo Clinic Proceedings*; 2019: Elsevier. <https://doi.org/10.1016/j.mayocp.2019.03.035> PMID: 31623843
41. Arroyave G, Mejía LA. Five decades of vitamin A studies in the region of Central America and Panama. *Food and nutrition bulletin*. 2010; 31(1):118–29. <https://doi.org/10.1177/156482651003100112> PMID: 20461909
42. Mejia LA, Arroyave G. The effect of vitamin A fortification of sugar on iron metabolism in preschool children in Guatemala. *The American journal of clinical nutrition*. 1982; 36(1):87–93. <https://doi.org/10.1093/ajcn/36.1.87> PMID: 7091038
43. Gabriel FR, Suen VM, Marchini JS, de Oliveira JED. High doses of vitamin A impair iron absorption. *Nutrition and Dietary Supplements*. 2012; 4:61–5.
44. Walczyk T, Davidsson L, Rossander-Hulthen L, Hallberg L, Hurrell RF. No enhancing effect of vitamin A on iron absorption in humans. *The American journal of clinical nutrition*. 2003; 77(1):144–9. <https://doi.org/10.1093/ajcn/77.1.144> PMID: 12499334
45. Michelazzo FB, Oliveira JM, Stefanello J, Luzia LA, Rondó PH. The influence of vitamin A supplementation on iron status. *Nutrients*. 2013; 5(11):4399–413. <https://doi.org/10.3390/nu5114399> PMID: 24212089
46. Menendez C, Fleming A, Alonso P. Malaria-related anaemia. *Parasitology today*. 2000; 16(11):469–76. [https://doi.org/10.1016/s0169-4758\(00\)01774-9](https://doi.org/10.1016/s0169-4758(00)01774-9) PMID: 11063857
47. Mwangi MN, Maskey S, Andang'o PE, Shinali NK, Roth JM, Trijsburg L, et al. Diagnostic utility of zinc protoporphyrin to detect iron deficiency in Kenyan pregnant women. *BMC medicine*. 2014; 12(1):229. <https://doi.org/10.1186/s12916-014-0229-8> PMID: 25428714

48. Zimmermann MB, Molinari L, Staubli-Asobayire F, Hess SY, Chaouki N, Adou P, et al. Serum transferrin receptor and zinc protoporphyrin as indicators of iron status in African children. *The American journal of clinical nutrition*. 2005; 81(3):615–23. <https://doi.org/10.1093/ajcn/81.3.615> PMID: 15755831
49. Kanuri G, Chichula D, Sawhney R, Kuriakose K, De'Souza S, Pais F, et al. Optimizing diagnostic biomarkers of iron deficiency anemia in community-dwelling Indian women and preschool children. *haematologica*. 2018; 103(12):1991–6. <https://doi.org/10.3324/haematol.2018.193243> PMID: 30093400
50. Zimmermann MB. Methods to assess iron and iodine status. *Br J Nutr*. 2008; 99 Suppl 3:S2–9. <https://doi.org/10.1017/S000711450800679X> PMID: 18598585
51. Heller LE, Roepe PD. Quantification of free ferriprotoporphyrin IX heme and hemozoin for artemisinin sensitive versus delayed clearance phenotype *Plasmodium falciparum* malarial parasites. *Biochemistry*. 2018; 57(51):6927–34. <https://doi.org/10.1021/acs.biochem.8b00959> PMID: 30513202
52. Iyer JK, Shi L, Shankar AH, Sullivan DJ. Zinc protoporphyrin IX binds heme crystals to inhibit the process of crystallization in *Plasmodium falciparum*. *Molecular medicine*. 2003; 9(5–8):175–82. <https://doi.org/10.2119/2003-00010.sullivan> PMID: 14571325
53. Ojukwu JU, Okebe JU, Yahav D, Paul M. Oral iron supplementation for preventing or treating anaemia among children in malaria-endemic areas. *Cochrane Database Syst Rev*. 2009(3):CD006589. <https://doi.org/10.1002/14651858.CD006589.pub2> PMID: 19588399
54. Bergdahl B, Bogentoft C, Jonsson UE, Magnusson JO. Fasting and postprandial absorption of digoxin from a microencapsulated formulation. *Eur J Clin Pharmacol*. 1983; 25(2):207–10. <https://doi.org/10.1007/BF00543792> PMID: 6628502
55. Olver JS, Burrows GD, Norman TR. The treatment of depression with different formulations of venlafaxine: a comparative analysis. *Hum Psychopharmacol*. 2004; 19(1):9–16. <https://doi.org/10.1002/hup.551> PMID: 14716706
56. Baldi A, Bontempo V, Cheli F, Carli S, Sgoifo Rossi C, Dell'Orto V. Relative bioavailability of vitamin E in dairy cows following intraruminal administration of three different preparations of DL-alpha-tocopheryl acetate. *Vet Res*. 1997; 28(6):517–24. PMID: 9428145
57. Armitage AE, Moretti D. The importance of iron status for young children in low-and middle-income countries: A narrative review. *Pharmaceuticals*. 2019; 12(2):59. <https://doi.org/10.3390/ph12020059> PMID: 30995720